We’ll help you find the highest quality medicine that you need.
Volibris
(Ambrisentan) is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment.
Manufactured by: Gilead Sciences, Inc.
Active Ingredient(s): Ambrisentan
Dosage Form: Tablet, oral
Strength: 5 mg
FDA approved: It is registered as Letairis in the US; FDA approval June 15, 2007
More information about Volibris: